Clearpoint Neuro (CLPT) Stock Price

Clearpoint Neuro Price

NASDAQ·CLOSED
14.70USD+0.13 (+0.89 %)
Market closed

Revenue has compounded at 18.9% per year over the past 17 years to 36.97 M USD. Clearpoint Neuro's net margin stands at -69.1%, up from -88.4% several years earlier. Analysts set a median price target of 28.56 USD, implying 94.3% above the current price. Of 8 analysts, 7 rate the stock a buy — an overall Buy consensus. The stock trades about 70% above its 52-week low.

Clearpoint Neuro stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Clearpoint Neuro over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Clearpoint Neuro stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Clearpoint Neuro's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Clearpoint Neuro Stock Price History
DateClearpoint Neuro Price
8/12/202614.70 USD
8/10/202614.57 USD
8/7/202614.21 USD
8/6/202613.39 USD
8/5/202612.96 USD
8/4/202612.83 USD
8/3/202615.38 USD
7/31/202614.94 USD
7/30/202614.58 USD
7/29/202614.18 USD
7/27/202614.40 USD
7/23/202614.49 USD
7/22/202615.03 USD
7/21/202615.41 USD
7/20/202615.05 USD
7/17/202615.15 USD
7/16/202615.06 USD
7/15/202615.67 USD
7/14/202615.96 USD
7/13/202616.70 USD
7/10/202617.50 USD
7/9/202617.88 USD
7/8/202616.93 USD
7/7/202617.48 USD
7/6/202618.57 USD
7/2/202618.72 USD
7/1/202618.72 USD
6/30/202617.84 USD
6/29/202619.43 USD
6/26/202618.48 USD
6/25/202617.96 USD
6/24/202617.98 USD
6/23/202618.53 USD
6/22/202617.29 USD
6/18/202617.77 USD
6/17/202616.81 USD
6/16/202613.34 USD
6/15/202613.52 USD
6/12/202613.44 USD
6/11/202613.84 USD
6/10/202614.08 USD
6/9/202613.59 USD
6/8/202613.38 USD
6/5/202612.89 USD
6/4/202614.32 USD
6/3/202613.30 USD
6/2/202612.37 USD
6/1/202612.64 USD
5/29/202612.67 USD
5/28/202612.24 USD
5/27/202611.50 USD
5/26/202611.82 USD
5/22/202611.44 USD
5/21/202611.70 USD
5/20/202611.20 USD
5/19/202611.17 USD
5/18/202611.13 USD
5/15/202611.64 USD
5/14/202612.77 USD
5/13/202612.19 USD
5/12/202612.64 USD
5/11/202612.31 USD
5/8/202612.82 USD
5/7/202611.68 USD
5/6/202611.47 USD
5/5/202611.10 USD
5/4/202611.18 USD
5/1/202611.37 USD
4/30/202611.18 USD
4/29/202610.34 USD
4/28/202611.08 USD
4/27/202611.21 USD
4/24/202611.78 USD
4/23/202610.82 USD
4/22/202610.99 USD
4/21/202610.72 USD
4/20/202611.16 USD
4/17/202611.79 USD
4/16/202610.50 USD
4/15/202610.46 USD
4/14/202610.38 USD
4/13/202610.01 USD
4/10/20268.68 USD
4/9/20268.96 USD
4/8/20269.17 USD
4/7/20269.07 USD
4/6/20269.38 USD
4/2/20269.37 USD
4/1/20269.14 USD
3/31/20269.10 USD
3/30/20268.66 USD
3/27/20269.07 USD
3/26/20269.39 USD
3/25/20269.49 USD
3/24/20269.42 USD
3/23/20269.51 USD
3/20/20269.03 USD
3/19/20269.18 USD
3/18/20269.61 USD
3/17/202611.16 USD
3/16/202611.03 USD
3/13/202610.79 USD
3/12/202611.53 USD
3/11/202611.62 USD
3/10/202611.32 USD
3/9/202611.54 USD
3/6/202610.00 USD
3/5/20269.25 USD
3/4/20268.94 USD
3/3/20268.84 USD
3/2/20269.80 USD
2/27/202612.57 USD
2/26/202614.43 USD
2/25/202615.16 USD
2/24/202614.55 USD
2/23/202614.76 USD
2/20/202614.15 USD
2/19/202614.35 USD
2/18/202614.19 USD
2/17/202613.58 USD
2/13/202613.55 USD
2/12/202613.04 USD
2/11/202613.37 USD
2/10/202613.59 USD
2/9/202614.11 USD
2/6/202613.46 USD
2/5/202612.57 USD
2/4/202613.31 USD
2/3/202613.94 USD
2/2/202613.24 USD
1/30/202612.93 USD
1/29/202613.42 USD
1/28/202613.43 USD
1/27/202614.39 USD
1/26/202614.20 USD
1/23/202615.68 USD
1/22/202614.21 USD
1/21/202614.01 USD
1/20/202613.90 USD
1/16/202614.65 USD
1/15/202614.65 USD
1/14/202615.41 USD
1/13/202614.47 USD
1/12/202615.65 USD
1/9/202614.92 USD
1/8/202615.31 USD
1/7/202615.29 USD
1/6/202615.27 USD
1/5/202614.19 USD
1/2/202614.03 USD
12/31/202513.68 USD
12/30/202513.57 USD
12/29/202513.65 USD
12/26/202514.02 USD
12/24/202514.49 USD
12/23/202514.37 USD
12/22/202514.61 USD
12/19/202514.20 USD
12/18/202513.65 USD
12/17/202513.56 USD
12/16/202513.82 USD
12/15/202512.38 USD
12/12/202512.71 USD
12/11/202512.97 USD
12/10/202513.11 USD
12/9/202513.43 USD
12/8/202513.69 USD
12/5/202513.54 USD
12/4/202514.06 USD
12/3/202514.08 USD
12/2/202513.34 USD
12/1/202513.74 USD
11/28/202514.46 USD
11/26/202514.44 USD
11/25/202514.60 USD
11/24/202514.40 USD
11/21/202513.82 USD
11/20/202513.51 USD
11/19/202513.99 USD
11/18/202514.30 USD
11/17/202514.21 USD
11/14/202515.43 USD
11/13/202515.50 USD
11/12/202516.71 USD
11/11/202517.40 USD
11/10/202516.53 USD
11/7/202515.81 USD
11/6/202518.23 USD
11/5/202516.98 USD
11/4/202517.52 USD
11/3/202519.00 USD
10/31/202523.22 USD
10/30/202523.68 USD
10/29/202524.11 USD
10/28/202526.98 USD
10/27/202525.46 USD
10/24/202524.74 USD
10/23/202525.27 USD
10/22/202524.29 USD
10/21/202524.98 USD
10/20/202527.32 USD
10/17/202525.38 USD
10/16/202525.28 USD
10/15/202524.83 USD
10/14/202526.03 USD
10/13/202526.27 USD
10/10/202526.11 USD
10/9/202528.96 USD
10/8/202529.60 USD
10/7/202526.39 USD
10/6/202526.59 USD
10/3/202527.38 USD
10/2/202525.05 USD
10/1/202520.91 USD
9/30/202521.79 USD
9/29/202521.57 USD
9/26/202521.55 USD
9/25/202519.74 USD
9/24/202519.28 USD
9/23/202512.16 USD
9/22/202512.03 USD
9/19/202511.20 USD
9/18/202511.35 USD
9/17/202510.66 USD
9/16/202510.65 USD
9/15/202510.47 USD
9/12/202510.49 USD
9/11/202511.09 USD
9/10/202510.53 USD
9/9/202510.95 USD
9/8/202510.93 USD
9/5/202511.05 USD
9/4/202511.08 USD
9/3/202510.25 USD
9/2/202510.43 USD
8/29/202510.49 USD
8/28/202510.49 USD
8/27/202510.64 USD
8/26/202510.64 USD
8/25/202510.50 USD
8/22/202510.70 USD
8/21/202510.24 USD
8/20/202510.37 USD
8/19/202510.46 USD
8/18/202511.22 USD
8/15/202511.55 USD
Access this data via the Eulerpool API
Get Free API Key

Clearpoint Neuro Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
20.55 M USD
-16.35 M USD
-16.44 M USD
Jan 1, 2023
23.96 M USD
-22.45 M USD
-22.09 M USD
Jan 1, 2024
31.39 M USD
-19.75 M USD
-18.91 M USD
Jan 1, 2025
36.97 M USD
-24.31 M USD
-25.54 M USD
Jan 1, 2026 (e)
53.13 M USD
-19.49 M USD
-33.12 M USD
Jan 1, 2027 (e)
64.10 M USD
-23.52 M USD
-27.97 M USD
Jan 1, 2028 (e)
77.10 M USD
-28.28 M USD
-25.88 M USD
Jan 1, 2029 (e)
92.10 M USD
-33.79 M USD
-19.34 M USD

Clearpoint Neuro Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 15, 2026, 1:06 AM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
2014201520162017201820192020202120222023202420252026e2027e2028e2029e
3.004.005.007.007.0011.0012.0016.0020.0023.0031.0036.0053.0064.0077.0092.00
–33.3325.0040.00–57.149.0933.3325.0015.0034.7816.1347.2220.7520.3119.48
33.3350.0060.0057.1457.1463.6475.0068.7565.0056.5261.2961.1161.1161.1161.1161.11
1.002.003.004.004.007.009.0011.0013.0013.0019.0022.0032.3939.1147.0656.22
-5.00-8.00-7.00-6.00-5.00-4.00-5.00-13.00-16.00-22.00-19.00-24.00-19.00-23.00-28.00-33.00
-166.67-200.00-140.00-85.71-71.43-36.36-41.67-81.25-80.00-95.65-61.29-66.67-35.85-35.94-36.36-35.87
-4.00-8.00-8.00-7.00-6.00-5.00-6.00-14.00-16.00-22.00-18.00-25.00-33.00-27.00-25.00-19.00
-42.86100.00–-12.50-14.29-16.6720.00133.3314.2937.50-18.1838.8932.00-18.18-7.41-24.00
1.501.923.6110.5710.9315.1716.7222.5224.5324.6327.0328.3228.3228.3228.3228.32
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Clearpoint Neuro generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Clearpoint Neuro retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Clearpoint Neuro's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Clearpoint Neuro has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Clearpoint Neuro's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Clearpoint Neuro stock margins

The Clearpoint Neuro margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Clearpoint Neuro. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Clearpoint Neuro.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
68.24 %
-82.44 %
-88.41 %
Jan 1, 2022
65.84 %
-79.58 %
-79.97 %
Jan 1, 2023
56.83 %
-93.70 %
-92.21 %
Jan 1, 2024
60.92 %
-62.91 %
-60.25 %
Jan 1, 2025
61.38 %
-65.75 %
-69.08 %
Jan 1, 2026 (e)
61.38 %
-36.69 %
-62.34 %
Jan 1, 2027 (e)
61.38 %
-36.69 %
-43.63 %
Jan 1, 2028 (e)
61.38 %
-36.69 %
-33.57 %

Clearpoint Neuro Stock Revenue, EBIT, Earnings per Share

The Clearpoint Neuro earnings per share therefore indicates how much revenue Clearpoint Neuro has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
0.72 USD
-0.60 USD
-0.64 USD
Jan 1, 2022
0.84 USD
-0.67 USD
-0.67 USD
Jan 1, 2023
0.97 USD
-0.91 USD
-0.90 USD
Jan 1, 2024
1.16 USD
-0.73 USD
-0.70 USD
Jan 1, 2025
1.31 USD
-0.86 USD
-0.90 USD
Jan 1, 2026 (e)
1.79 USD
-0.69 USD
-1.11 USD
Jan 1, 2027 (e)
2.15 USD
-0.83 USD
-0.94 USD
Jan 1, 2028 (e)
2.59 USD
-1.00 USD
-0.87 USD

Clearpoint Neuro business model & stock analysis

Clearpoint Neuro Inc is a leading company in the medical technology industry that specializes in the development and marketing of advanced medical products and systems. The company was founded in 1998 and is headquartered in Irvine, California. Clearpoint Neuro's primary goal is to provide better care and treatment for patients with neurological disorders. Clearpoint Neuro was originally founded in 1998 under the name MRI Intervention to meet the market demand for innovative navigation systems for minimally invasive brain procedures. The company's initial products included imaging devices used during surgery. Since then, the company has expanded its product portfolio and strengthened its market position by focusing on core tasks in the field of medical technology. In 2011, MRI Intervention rebranded as Clearpoint Neuro to accommodate its growing product portfolio. The company now primarily focuses on the development and marketing of platform technologies for the control of minimally invasive instruments during neurosurgical procedures. Its customers include hospitals and research institutions that specialize in neurological and neuroscience applications. Clearpoint Neuro has built an extremely successful business model that specializes in providing advanced medical technology to benefit patients. The company works closely with leading neurosurgeons and researchers to understand the needs of patients and develop the most advanced technologies aimed at improving patient treatment. Clearpoint Neuro is a B2B (Business to Business) company that sells its products and services to hospitals and research institutions to ensure that its products are used by medical professionals with appropriate education and experience. The company also has a strong presence in the academic world, where it focuses on collaborating with laboratories and universities to advance the latest developments in technology and research. The divisions of Clearpoint Neuro include medical product areas developed from its technology base, which are described in more detail in the following sections. ClearPoint System ClearPoint is an intraoperative MRI system that is available as a core component of neurosurgical intervention platforms. It uses advanced technology for real-time localization and navigation of instruments to perform minimally invasive brain surgeries. It utilizes imaging technologies to enable navigation and coordination during the surgical procedure. ClearPoint Neuro Therapies ClearPoint Neuro Therapies includes three main areas: "DBS," "MRI-Guided Focused Ultrasound," and "Laser Therapy." DBS (Deep Brain Stimulation) is a minimally invasive neural therapy that involves the insertion of thin electrodes into the brain using a specially existing surgical technique to treat degenerative diseases, particularly Parkinson's disease. Another highly innovative therapy option is MRI-Guided Focused Ultrasound therapy, which targets and precisely destroys cancer cells using focused ultrasound waves. ClearPoint Neuro is one of the leading providers of this advanced therapy. Laser therapy involves the destruction of selected neural cells using heat. ClearPoint Neuro Navigation ClearPoint Neuro's navigation technologies are leading in neurosurgery and research. Navigation allows for precise placement of needles in the brain to obtain biopsies under ultrasound guidance or to administer medication targetedly without damaging the brain. The system is used by neurosurgeons and researchers worldwide. In conclusion, Clearpoint Neuro Inc is a leading company in the medical technology industry that specializes in the development and manufacturing of advanced systems and products for neurosurgery and research. The company has built a strong business model by working closely with leading neurosurgeons and researchers and developing the most advanced technologies aimed at improving the quality of patient care. The ClearPoint System, ClearPoint Neuro Therapies, and ClearPoint Neuro Navigation divisions play a significant role in its success.

Clearpoint Neuro SWOT Analysis

Strengths

Clearpoint Neuro Inc. has several strengths that contribute to its competitive advantage in the market:

  • Advanced technology and innovative products
  • Strong intellectual property portfolio
  • Experienced and skilled workforce
  • Established brand reputation and customer loyalty
  • Strong partnerships and collaborations

Weaknesses

Despite its strengths, Clearpoint Neuro Inc. also faces certain weaknesses that may hinder its growth:

  • Limited market presence compared to competitors
  • Dependence on key customers or partners
  • High production costs
  • Relatively small scale of operations
  • Limited financial resources

Opportunities

Clearpoint Neuro Inc. can capitalize on the following opportunities to enhance its market position:

  • Growing demand for neurological devices and treatments
  • Expansion into emerging markets
  • Increasing research and development in the neuroscience field
  • Strategic alliances and acquisitions to expand product portfolio
  • Advancements in healthcare technology

Threats

Clearpoint Neuro Inc. should be aware of the following threats that may impact its business:

  • Intense competition from established companies
  • Regulatory and compliance challenges in the healthcare industry
  • Economic downturns affecting healthcare spending
  • Rapid technological advancements making current products obsolete
  • Vulnerability to cybersecurity risks

Clearpoint Neuro Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Clearpoint Neuro Employees
Details
Date
Clearpoint Neuro Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Clearpoint Neuro Segments

Clearpoint Neuro Revenue by Segment (1/3)

  • 3 Years

  • 5 Years

  • Max

Service and other revenue
Product Revenue
Product - Product Revenue
Subtotal - Functional Neurosurgery Navigation and Therapy
Subtotal - Biologics and Drug Delivery
Functional Neurosurgery Navigation and Therapy - Disposable Products
Product - Functional Neurosurgery
Functional Neurosurgery Navigation and Therapy
Biologics And Drug Delivery - Services And License Fees
Functional Neurology
Biologics and Drug Delivery Revenue
Service and Other Revenues
Biologics and Drug Delivery - Disposable Products
Biologics and Drug Delivery - Services
Subtotal - Capital Equipment and Software Revenue
Services - Service Revenue
Functional Neurosurgery Navigation and Therapy - Services
Capital Equipment and Software - Systems and Software Products
Capital Equipment and Software Revenue
Product - Biologics and Drug Delivery
Product - Capital Equipment
Biologics And Drug Delivery
Services - Biologics and Drug Delivery
Capital Equipment and Software - Services
Services - Capital Equipment and Other
Capital Equipment
Capital Equipment and Other
Remaining Performance Obligations Capital Equipment-Related Service Revenue Member]
Service - Therapy
Capital Equipment-Related Service Revenue Member]
Products - Therapy
Details
Date
Service and other revenue
Product Revenue
Product - Product Revenue
Subtotal - Functional Neurosurgery Navigation and Therapy
Subtotal - Biologics and Drug Delivery
Functional Neurosurgery Navigation and Therapy - Disposable Products
Product - Functional Neurosurgery
Functional Neurosurgery Navigation and Therapy
Biologics And Drug Delivery - Services And License Fees
Functional Neurology
Biologics and Drug Delivery Revenue
Service and Other Revenues
Biologics and Drug Delivery - Disposable Products
Biologics and Drug Delivery - Services
Subtotal - Capital Equipment and Software Revenue
Services - Service Revenue
Functional Neurosurgery Navigation and Therapy - Services
Capital Equipment and Software - Systems and Software Products
Capital Equipment and Software Revenue
Product - Biologics and Drug Delivery
Product - Capital Equipment
Biologics And Drug Delivery
Services - Biologics and Drug Delivery
Capital Equipment and Software - Services
Services - Capital Equipment and Other
Capital Equipment
Capital Equipment and Other
Remaining Performance Obligations Capital Equipment-Related Service Revenue Member]
Service - Therapy
Capital Equipment-Related Service Revenue Member]
Products - Therapy
Jan 1, 2018
0.00 USD
6.69 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
5.31 M USD
0.00 USD
668,246.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
951,940.00 USD
0.00 USD
0.00 USD
0.00 USD
420,039.00 USD
393,023.00 USD
303,912.00 USD
0.00 USD
142,605.00 USD
0.00 USD
Jan 1, 2019
0.00 USD
0.00 USD
9.48 M USD
0.00 USD
0.00 USD
0.00 USD
6.88 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
1.74 M USD
0.00 USD
0.00 USD
0.00 USD
1.46 M USD
1.04 M USD
0.00 USD
889,702.00 USD
0.00 USD
625,870.00 USD
0.00 USD
0.00 USD
0.00 USD
225,000.00 USD
0.00 USD
96,925.00 USD
Jan 1, 2020
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
6.27 M USD
0.00 USD
6.30 M USD
0.00 USD
0.00 USD
5.04 M USD
0.00 USD
1.47 M USD
3.58 M USD
0.00 USD
0.00 USD
25,000.00 USD
1.05 M USD
1.49 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
440,000.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2021
0.00 USD
0.00 USD
0.00 USD
8.07 M USD
6.80 M USD
7.70 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
3.35 M USD
3.44 M USD
1.43 M USD
0.00 USD
375,000.00 USD
864,000.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
569,000.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2022
0.00 USD
0.00 USD
0.00 USD
9.12 M USD
9.12 M USD
7.59 M USD
0.00 USD
0.00 USD
5.43 M USD
0.00 USD
0.00 USD
0.00 USD
3.69 M USD
0.00 USD
2.31 M USD
0.00 USD
1.54 M USD
1.51 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
795,000.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2023
13.35 M USD
10.60 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2024
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2025
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD

Clearpoint Neuro Revenue by Segment (2/3)

  • 3 Years

  • 5 Years

  • Max

Product revenue
Service and other revenue
Product Revenues
Service and Other Revenues
Details
Date
Product revenue
Service and other revenue
Product Revenues
Service and Other Revenues
Jan 1, 2018
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2019
9.48 M USD
0.00 USD
0.00 USD
1.74 M USD
Jan 1, 2020
0.00 USD
0.00 USD
8.79 M USD
4.04 M USD
Jan 1, 2021
11.91 M USD
4.39 M USD
0.00 USD
0.00 USD
Jan 1, 2022
12.79 M USD
7.76 M USD
0.00 USD
0.00 USD
Jan 1, 2023
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2024
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2025
23.86 M USD
13.11 M USD
0.00 USD
0.00 USD

Clearpoint Neuro Revenue by Segment (3/3)

  • 3 Years

  • 5 Years

  • Max

Biologics and drug delivery
Neurosurgery Navigation And Therapy
Capital equipment and software
Capital Equipment and Software-Related Service
Remaining Performance Obligations Capital Equipment-Related Service Revenue
Capital Equipment-Related Service Revenue
Remaining Performance Obligation Related to Capital Equipment and Software-Related Service Agreements
Details
Date
Biologics and drug delivery
Neurosurgery Navigation And Therapy
Capital equipment and software
Capital Equipment and Software-Related Service
Remaining Performance Obligations Capital Equipment-Related Service Revenue
Capital Equipment-Related Service Revenue
Remaining Performance Obligation Related to Capital Equipment and Software-Related Service Agreements
Jan 1, 2018
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2019
0.00 USD
0.00 USD
0.00 USD
0.00 USD
1.10 M USD
228,000.00 USD
0.00 USD
Jan 1, 2020
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
500,000.00 USD
500,000.00 USD
Jan 1, 2021
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2022
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2023
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2024
17.31 M USD
10.29 M USD
3.80 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2025
0.00 USD
0.00 USD
0.00 USD
2.10 M USD
0.00 USD
0.00 USD
0.00 USD

Clearpoint Neuro Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Clearpoint Neuro historical P/E ratio, EBIT multiple, and P/S ratio

Clearpoint Neuro annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Clearpoint Neuro shares outstanding

The number of shares of Clearpoint Neuro was 28.32 M in 2025. This indicates how many shares Clearpoint Neuro is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
22.52 M Stocks
Jan 1, 2022
24.53 M Stocks
Jan 1, 2023
24.63 M Stocks
Jan 1, 2024
27.03 M Stocks
Jan 1, 2025
28.32 M Stocks
Jan 1, 2026 (e)
28.32 M Stocks
Jan 1, 2027 (e)
28.32 M Stocks
Jan 1, 2028 (e)
28.32 M Stocks

Clearpoint Neuro stock splits

In Clearpoint Neuro's history, there have been no stock splits.

Current Clearpoint Neuro forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
87.50 % (7)
Hold
12.50 % (1)
Sell
0.00 % (0)
12M Price Target
28.56
Last Price
14.70
Currency
USD
12M Return Potential
94.29 %
LTM Return
0 %

Clearpoint Neuro Analyst Rating Actions

DateFirmActionRating
6/18/2026
B. Riley Securities
B. Riley Securities
MaintainedBuy
3/18/2026
B. Riley Securities
B. Riley Securities
MaintainedBuy
3/5/2026
B. Riley Securities
B. Riley Securities
MaintainedBuy
8/1/2025
Stifel
Stifel
MaintainedBuy
4/25/2025
B. Riley Securities
B. Riley Securities
MaintainedBuy
4/1/2025
Stifel
Stifel
MaintainedBuy
1/28/2025
B. Riley Securities
B. Riley Securities
MaintainedBuy
1/21/2025
Lake Street
Lake Street
MaintainedBuy
8/27/2024
Lake Street
Lake Street
MaintainedBuy
3/13/2024
Stifel
Stifel
MaintainedBuy

Clearpoint Neuro Earnings Calls

2025

Clearpoint Neuro Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/11/2026-0.29USD-12.99 MUSD-2026 Q2
5/13/2026-0.27USD-12.24 MUSD-2026 Q1
3/17/2026-0.20USD-10.25 MUSD-2025 Q4
8/12/2025-0.20USD-9.38 MUSD-2025 Q2
11/7/2024-0.18USD-7.94 MUSD-2024 Q3
5/9/2024-0.21USD-6.96 MUSD-2024 Q1
2/28/2024-0.21USD-6.34 MUSD-2023 Q4
8/7/2023-0.16USD-6.39 MUSD-2023 Q2
5/9/2023-0.17USD-5.68 MUSD-2023 Q1
2/27/2023-0.17USD-5.81 MUSD-2022 Q4

EESG©

Eulerpool ESG Scorecard© for the Clearpoint Neuro stock

38/100
44
Environment
25
Social
46
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Clearpoint Neuro shareholder structure

% Name
6.08737%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
5.93841%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
4.48119%
Bigger Capital Funds, LP
Bigger Capital Funds, LP
2.19948%
Geode Capital Management, L.L.C.
Geode Capital Management, L.L.C.
2.11113%
State Street Investment Management (US)
State Street Investment Management (US)
1.73235%
Millennium Management LLC
Millennium Management LLC
...

Clearpoint Neuro Beneficial Ownership Filings (SEC 13D/G)

Free Float
87.6%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
14.00%
PTC Therapeutics, Inc.
PTC Therapeutics, Inc.
SEC ↗
9.99%
E. Jeffrey Peierls(1)
E. Jeffrey Peierls(1)
SEC ↗
7.70%
2.
2.
SEC ↗
6.30%
MAK Capital Fund LP
MAK Capital Fund LP
SEC ↗
6.00%
(1) BlackRock, Inc.
(1) BlackRock, Inc.
SEC ↗
5.80%
Page 1 of 5
Page 1 of 5
SEC ↗
5.60%
BlackRock, Inc.
BlackRock, Inc.
SEC ↗
5.60%
Mellon Group, LLC
Mellon Group, LLC
SEC ↗
5.32%
The Vanguard Group - 23-1945930
The Vanguard Group - 23-1945930
SEC ↗
4.90%
only).
only).
SEC ↗

Clearpoint Neuro Executives and Management Board

11 members · avg. age 58 · 27 % women

JB

Mr. Joseph Burnett (48)

President, Chief Executive Officer, Director · since 2017

2.53 M USD

Management

DA

Mr. Danilo D' Alessandro (40)

Chief Financial Officer

1.17 M USD
JS

Mr. Jeremy Stigall (42)

Chief Business Officer

1.13 M USD
MS

Mr. Mazin Sabra (45)

Chief Operating Officer

–

Board of Directors

RF

Mr. R. John Fletcher (79)

Independent Chairman of the Board

227,199.00 USD
LF

Ms. Lynnette Fallon (65)

Independent Director

202,495.00 USD
TR

Mr. Timothy Richards (67)

Independent Director

193,957.00 USD
BJ

Ms. B. Kristine Johnson (73)

Independent Director

189,995.00 USD
PG

Mr. Pascal Girin (65)

Independent Director

188,412.00 USD
LL

Dr. Linda Liau (58)

Independent Director

182,339.00 USD

Clearpoint Neuro Supply Chain

Clearpoint Neuro Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
4 companies
#NameTrend
1
Koninklijke Philips
Supplier·Customer·Health Care Equipment & Supplies·NL
0.01
-0.21
0.40
0.49
0.92
0.41
2
Siemens Healthineers
Supplier·Customer·Health Care Equipment & Supplies·DE
0.45
0.62
0.63
0.75
0.01
0.30
#NameTrend
1
Voyager Therapeutics
Supplier·Customer·Biotechnology·US
-0.17
0.19
0.59
-0.11
-0.41
-0.59
2
Clinical Laserthermia Systems B
Supplier·Customer·SE
0.02
0.17
0.75
0.64
0.33
-0.53

Frequently asked questions about Clearpoint Neuro

Clearpoint Neuro Inc's business model focuses on developing and commercializing innovative medical devices for a variety of neurosurgical procedures. The company primarily specializes in providing advanced technology solutions for neurologists and neurosurgeons, empowering them to precisely deliver therapeutic interventions to the brain. Clearpoint Neuro Inc's flagship product, the ClearPoint Neuro Navigation System, enables real-time MRI-guided neurosurgery, enhancing accuracy and patient outcomes. By combining imaging technology with surgical instruments, the company aims to revolutionize neurosurgical procedures. Clearpoint Neuro Inc's business model revolves around providing cutting-edge solutions that improve the precision, safety, and efficacy of neurosurgical interventions, ultimately benefiting patients and healthcare professionals alike.

Clearpoint Neuro Inc is primarily active in the medical device industry.

The main competitors of Clearpoint Neuro Inc in the market include companies such as Medtronic, Inc., Stryker Corporation, and Brainlab AG.

Clearpoint Neuro Inc is a medical technology company specializing in the development and commercialization of devices for neurological procedures. Founded in 1999, Clearpoint Neuro has established itself as a leader in the field of image-guided neurosurgery. The company's innovative platform combines real-time MRI technology with surgical planning software, enabling precise targeting and accurate delivery of therapies to the brain. Clearpoint Neuro's devices have been utilized in various clinical applications, including the treatment of movement disorders, brain tumors, and epilepsy. With its commitment to advancing neurosurgical interventions, Clearpoint Neuro continues to push the boundaries of neuroscience to improve patient outcomes.

Clearpoint Neuro Inc has achieved several significant milestones. The company established itself as a leader in the field of neurosurgery by developing and commercializing a unique and innovative MRI-guided neurosurgical system called Clearpoint. This system allows precise and real-time guidance for brain surgeries, enhancing patient outcomes and reducing risks. In addition, Clearpoint Neuro Inc has successfully obtained regulatory clearances for its products in multiple countries, expanding its global reach. The company has also formed strategic partnerships with renowned medical institutions and received recognition for its advancements in neurosurgery. Clearpoint Neuro Inc continues to make advancements in the field, solidifying its position as a trusted provider of innovative neurosurgical solutions.

Clearpoint Neuro Inc is primarily present in the United States.

Clearpoint Neuro Inc represents values of innovation, patient-focused care, and collaboration in the field of neurosurgery and neuromodulation. The company strives to improve patient outcomes by developing advanced technologies and solutions tailored to meet the unique needs of neurosurgeons. Clearpoint Neuro is dedicated to providing precision-guided therapies and enabling targeted delivery of therapies to the brain. Their corporate philosophy emphasizes the importance of cutting-edge research, strategic partnerships, and continuous improvement to drive advancements in neurological treatments. With a commitment to excellence, Clearpoint Neuro aims to make a significant impact in the lives of patients suffering from neurological disorders.

Analysts currently set an average price target of 28.56 USD for the Clearpoint Neuro stock (median: 28.56 USD), implying +94.3 % versus the latest price. The consensus is based on 8 analyst ratings.

Clearpoint Neuro Analyst Price Targets 2026

8 analysts currently rate the Clearpoint Neuro stock: 7 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Clearpoint Neuro to generate revenue of 53.13 M USD and earnings per share of -1.17 USD.

Clearpoint Neuro Analyst Price Targets 2026

Converted at the current exchange rate, the Clearpoint Neuro share trades at 12.75 EUR (14.70 USD).

The Clearpoint Neuro share (CLPT) is listed on 1 stock exchanges, including: NASDAQ (CLPT).

Clearpoint Neuro Inc. is an innovative company in the field of medical devices and imaging technologies. The company is headquartered in Irvine, California and operates worldwide. Clearpoint Neuro offers a wide range of solutions for the assessment of brain and central nervous system diseases. Clearpoint Neuro's business model is based on several divisions. On one hand, the company specializes in the development of imaging technologies and surgical instruments for the placement of electrodes and catheters in the brain. This includes the Clearpoint Neuro Navigation System and the SmartFrame®. The Clearpoint Neuro Navigation System allows neurosurgeons to combine electrophysiological and imaging data in real-time during surgical procedures. With the support of this system, neurosurgeons can determine the position of electrodes and catheters more precisely to perform targeted therapies for patients with Parkinson's, epilepsy, and other neurological diseases. The SmartFrame® is an instrument for the placement of catheters and probes in the brain and spine. It provides an extremely precise and reliable method for positioning drug pumps and other instruments for the treatment of pain as well as neurological or psychiatric disorders. In addition, Clearpoint Neuro also offers services such as training medical professionals in the effective use of navigation technology and surgical instruments. A third division of the company is the Clearpoint Neuro Customer Service team. This team provides comprehensive support to customers for any questions related to products and services. It is available for all inquiries and offers training, technical support, and other services. Another important area is the sale of consumables such as catheters and electrodes for electrophysiology. The company has a wide range of high-performance catheters specifically designed for use with the Clearpoint Neuro Navigation System. Clearpoint Neuro also has strategic partnerships with leading medical institutions and research facilities worldwide. These partnerships contribute to the advancement and improvement of Clearpoint Neuro products and provide a platform for future innovations and technologies. In summary, Clearpoint Neuro offers a broad portfolio of products and services for the assessment and treatment of neurological and central nervous system diseases. The company is committed to meeting the needs and requirements of its customers by providing innovative technologies and collaborating closely with its growing customer base.

The expected revenue of Clearpoint Neuro is 53.13 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Clearpoint Neuro is -33.12 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Clearpoint Neuro is currently -12.57. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Clearpoint Neuro stock.

The price-to-sales ratio (P/S) of Clearpoint Neuro is currently 7.83. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Clearpoint Neuro stock.

The Eulerpool Quality Score for Clearpoint Neuro is 4/10.

The ISIN of Clearpoint Neuro is US18507C1036. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Clearpoint Neuro is A2PZ3E. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Clearpoint Neuro is CLPT. The ticker symbol is used to trade Clearpoint Neuro shares on the stock exchange.

Clearpoint Neuro paid dividends every year for the past 0 years.

Clearpoint Neuro is assigned to the 'Health' sector.

The dividends of Clearpoint Neuro are distributed in USD.

All fundamentals and in-depth analysis of Clearpoint Neuro

Our stock analysis for Clearpoint Neuro stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Clearpoint Neuro. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Clearpoint Neuro Stock
Clearpoint Neuro Revenue→
Clearpoint Neuro Stock
Clearpoint Neuro Net Income→
Clearpoint Neuro Stock
Clearpoint Neuro P/E→
Clearpoint Neuro Stock
Clearpoint Neuro P/S→
Clearpoint Neuro Stock
Clearpoint Neuro EBIT→
Clearpoint Neuro Stock
Clearpoint Neuro Dividend→
Clearpoint Neuro Stock
Clearpoint Neuro Directors Dealings→
Clearpoint Neuro Stock
Clearpoint Neuro Stocks→
Clearpoint Neuro Stock
Clearpoint Neuro Market capitalization→
Clearpoint Neuro Stock
Clearpoint Neuro Debt→
Clearpoint Neuro Stock
Clearpoint Neuro Liabilities→
Clearpoint Neuro Stock
Clearpoint Neuro Equity→
Clearpoint Neuro Stock
Clearpoint Neuro AAQS→
Clearpoint Neuro Stock
Clearpoint Neuro Employees→
Clearpoint Neuro Stock
Clearpoint Neuro ROE→
Clearpoint Neuro Stock
Clearpoint Neuro ROA→
Clearpoint Neuro Stock
Clearpoint Neuro ROCE→
Clearpoint Neuro Stock
Clearpoint Neuro News→
Clearpoint Neuro Stock
Clearpoint Neuro Analyst Price Targets→

Health Stocks

Clearside BiomedicalClearmind MedicineCleneClearbridge HealthCleopatra Hospital SAECleanspace HoldingsClever Culture SystemsClassysClever Leaves HoldingsClarity PharmaceuticalsClimb BioClarity Medical Group HoldingAll Stocks A–Z →